Marshall Wace LLP bought a new stake in shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund bought 2,634,065 shares of the biotechnology company's stock, valued at approximately $6,532,000. Marshall Wace LLP owned approximately 3.69% of Aclaris Therapeutics at the end of the most recent reporting period.
Several other institutional investors have also made changes to their positions in ACRS. ExodusPoint Capital Management LP purchased a new position in shares of Aclaris Therapeutics during the 4th quarter valued at $26,000. Invesco Ltd. bought a new stake in shares of Aclaris Therapeutics in the 4th quarter valued at approximately $28,000. Commonwealth Equity Services LLC acquired a new position in Aclaris Therapeutics in the fourth quarter worth approximately $36,000. Charles Schwab Investment Management Inc. bought a new position in Aclaris Therapeutics during the fourth quarter valued at approximately $82,000. Finally, XTX Topco Ltd acquired a new stake in Aclaris Therapeutics in the fourth quarter valued at approximately $111,000. 98.34% of the stock is currently owned by institutional investors and hedge funds.
Aclaris Therapeutics Stock Down 2.6 %
ACRS stock traded down $0.04 during mid-day trading on Tuesday, reaching $1.33. 125,264 shares of the stock traded hands, compared to its average volume of 907,510. The business has a 50-day moving average of $1.54 and a two-hundred day moving average of $2.24. The firm has a market capitalization of $143.47 million, a PE ratio of -2.55 and a beta of 0.53. Aclaris Therapeutics, Inc. has a 52 week low of $0.95 and a 52 week high of $5.17.
Analyst Ratings Changes
Several brokerages have recently commented on ACRS. Cantor Fitzgerald started coverage on shares of Aclaris Therapeutics in a research note on Tuesday, March 18th. They set an "overweight" rating on the stock. Scotiabank began coverage on shares of Aclaris Therapeutics in a research report on Friday, March 7th. They set a "sector outperform" rating and a $15.00 target price on the stock. Finally, StockNews.com cut Aclaris Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday, February 8th. One equities research analyst has rated the stock with a sell rating, seven have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Aclaris Therapeutics presently has an average rating of "Moderate Buy" and an average price target of $11.67.
View Our Latest Stock Analysis on Aclaris Therapeutics
About Aclaris Therapeutics
(
Free Report)
Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.
Read More
Before you consider Aclaris Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aclaris Therapeutics wasn't on the list.
While Aclaris Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
